Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Indolent Non-Hodgkin Lymphoma × ibrutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 58 Lymphoma, Mantle-Cell 36 Waldenstrom Macroglobulinemia 18 Lymphoma, Large B-Cell, Diffuse 14 Lymphoma, Follicular 13 Recurrence 10 Lymphoma, B-Cell, Marginal Zone 10 Leukemia 9 Lymphoma 8 Neoplasms 7 Lymphoma, B-Cell 7 Lymphoma, Non-Hodgkin 4 Leukemia, Myeloid, Acute 3 Leukemia, B-Cell 3 Hodgkin Disease 3 Hematologic Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms, Plasma Cell 2 Multiple Myeloma 2 Leukemia, Prolymphocytic 2 Glioblastoma 2 Carcinoma, Non-Small-Cell Lung 2 Bronchiolitis Obliterans Syndrome 2 Brain Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Smoldering Multiple Myeloma 1 Prostatic Neoplasms 1 Primary Central Nervous System Lymphoma (PCNSL) 1 Neurologic Manifestations 1 Neuroectodermal Tumors, Primitive 1

Interventions

obinutuzumab 1 ibrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02689869 2021-05-07

Alternative

Ludwig-Maximilians - University of Munich

Phase 2 Unknown

Indolent Non-Hodgkin Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡